University of Surrey

Test tubes in the lab Research in the ATI Dance Research

13-cis-Retinoic Acid in Combination with Gemcitabine in the Treatment of Locally Advanced and Metastatic Pancreatic Cancer - Report of a Pilot Phase II Study

Michael, A, Hill, M, Maraveyas, A, Dalgleish, A and Lofts, F (2007) 13-cis-Retinoic Acid in Combination with Gemcitabine in the Treatment of Locally Advanced and Metastatic Pancreatic Cancer - Report of a Pilot Phase II Study Clinical Oncology, 19 (2). pp. 150-153.

[img] Text
13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer.pdf
Restricted to Repository staff only

Download (71kB)

Abstract

Aims: Adenocarcinoma of the pancreas is a cancer with extremely poor prognosis and limited therapeutic options. Retinoids are derivatives of vitamin A involved in the control of many biological functions, including cell growth and differentiation and the induction of apoptosis. On the basis of pre-clinical evidence and some clinical data, we conducted a phase II study of 13-cis-retinoic acid (13-cis-RA) in combination with gemcitabine in patients with unresectable pancreatic carcinoma. Materials and methods: Patients with histologically confirmed unresectable pancreatic carcinoma were treated with gemcitabine 1000 mg/m2 on days 8, 15, 22 plus 13-cis-RA 1 mg/kg on days 1e14 for six cycles. The end points included the objective response rate and median survival. Results: Thirty patients were recruited, 15 men and 15 women; 20 patients were evaluable. The median age was 65 years (range 44e79 years) and the median Karnofsky performance status was 80% (range 60e100%). The median followup was 21 months. One patient achieved a partial remission, seven patients had stable disease and 12 patients developed progressive disease. Toxicity was mainly haematological, with eight cases of grade 3 and four cases of grade 4 neutropenia, thrombocytopenia and anaemia. The median survival was 7.8 months (range 2.6e21.6 months). Conclusions: The combination of gemcitabine and 13-cis-RA was well tolerated, but we did not see improvement in the response rate. Further studies with other retinoids may be beneficial to patients with unresectable pancreatic cancer.

Item Type: Article
Divisions : Faculty of Health and Medical Sciences > School of Biosciences and Medicine > Department of Microbial and Cellular Sciences
Authors :
NameEmailORCID
Michael, AUNSPECIFIEDUNSPECIFIED
Hill, MUNSPECIFIEDUNSPECIFIED
Maraveyas, AUNSPECIFIEDUNSPECIFIED
Dalgleish, AUNSPECIFIEDUNSPECIFIED
Lofts, FUNSPECIFIEDUNSPECIFIED
Date : 2007
Identification Number : 10.1016/j.clon
Additional Information : NOTICE: this is the author’s version of a work that was accepted for publication in Clinical Oncology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Clinical Oncology, 19(2), March 2007, doi:10.1016/j.clon.
Depositing User : Symplectic Elements
Date Deposited : 28 Mar 2017 14:39
Last Modified : 31 Oct 2017 14:26
URI: http://epubs.surrey.ac.uk/id/eprint/210453

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800